The impact of Tα1 on reducing complications in LC patients who receive CCRT plus immunotherapy consolidation is something to look forward to because it makes it possible to perform consolidation immunotherapy after CCRT by reducing complications like RP associated with CCRT. The gene discussed is TAAR1; the disease is laryngotracheoesophageal cleft.